XSPRAY — Xspray Pharma publ AB Share News
0.000.00%
Last trade - 00:00- SEK631.98m
- SEK659.11m
Brief: Xspray Q1 Revenue SEK 0
Brief: Xspray Pharma Re-Submits FDA Application
Brief: Xspray Q4 Revenue SEK 0
Brief: XSpray Pharma Changes Timeline For Dasynoc FDA Application Sumbission
Brief: Xspray Pharma To Get About SEK 135 Mln From Rights Issue
Brief: Xspray Q3 Revenue SEK 0
Brief: Xspray Resolves On Rights Issue Of About SEK 135 Mln, Raises Loan Of SEK 100 Mln
Brief: XSpray Pharma Announces Positive FDA Meeting, Plans For Dasynoc NDA Resubmission
Brief: Xspray Pharma Announces Positive FDA Meeting, Plans For Dasynoc NDA Resubmission
Brief: Xspray Q2 Revenue SEK 0
Brief: Flerie Purchased Shares In Xspray Pharma For Approx. Sek 5.6 Mln
Brief: Xspray Pharma's XS003 Study Shows Matching Bioavailability To Tasigna At More Than A 50% Lower Dose
Brief: Xspray Q1 Revenue SEK 0
Brief: XSpray Pharma Raises SEK 100.3 Mln Through Warrants To6
Brief: Xspray Pharma To Advance Fourth Product Candidate XS015 Into Clinical Trials
Brief: Östersjöstiftelsen Intends To Exercise TO6 Warrants Of Xspray Pharma
Brief: Xspray Pharma Raises SEK 92.3 Million Through Warrants TO5
Brief: Xspray Pharma Comments On Dasynoc, Sprycel Uptake
Brief: Xspray Q3 Adjusted EPS SEK -1.59